Maia Biotechnology (MAIA) said Tuesday that it has amended a 2021 clinical supply deal with Regeneron (REGN) to cover the expansion of a phase 2 clinical trial evaluating investigational drug THIO in non-small cell lung cancer.
According to the terms of the amended clinical supply agreement, Maia said Regeneron will provide its cancer drug Libtayo to treat all participants in the trial, including the additional patients in the expansion portion of the study.
The expansion part of the trial will further evaluate the efficacy of THIO sequenced with Libtayo in advanced non-small cell lung cancer patients receiving third-line therapy who were resistant to previous checkpoint inhibitor treatments and chemotherapy, Maia said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。